Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 57.61
EXAS's Cash-to-Debt is ranked higher than
66% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. EXAS: 57.61 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.24  Med: No Debt Max: No Debt
Current: 57.61
Equity-to-Asset 0.88
EXAS's Equity-to-Asset is ranked higher than
92% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. EXAS: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.75 Max: 0.96
Current: 0.88
-0.41
0.96
Piotroski F-Score: 5
Altman Z-Score: 46.66
Beneish M-Score: -1.47
WACC vs ROIC
9.00%
-487.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -117.85
EXAS's Operating Margin % is ranked lower than
77% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. EXAS: -117.85 )
Ranked among companies with meaningful Operating Margin % only.
EXAS' s Operating Margin % Range Over the Past 10 Years
Min: -5591.71  Med: -420.54 Max: 1150.29
Current: -117.85
-5591.71
1150.29
Net Margin % -116.39
EXAS's Net Margin % is ranked lower than
78% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. EXAS: -116.39 )
Ranked among companies with meaningful Net Margin % only.
EXAS' s Net Margin % Range Over the Past 10 Years
Min: -5564.4  Med: -403.8 Max: 1123.53
Current: -116.39
-5564.4
1123.53
ROE % -50.06
EXAS's ROE % is ranked lower than
73% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. EXAS: -50.06 )
Ranked among companies with meaningful ROE % only.
EXAS' s ROE % Range Over the Past 10 Years
Min: -505.37  Med: -50.88 Max: -26.92
Current: -50.06
-505.37
-26.92
ROA % -44.38
EXAS's ROA % is ranked lower than
74% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. EXAS: -44.38 )
Ranked among companies with meaningful ROA % only.
EXAS' s ROA % Range Over the Past 10 Years
Min: -95.07  Med: -45.88 Max: -18.9
Current: -44.38
-95.07
-18.9
ROC (Joel Greenblatt) % -409.50
EXAS's ROC (Joel Greenblatt) % is ranked lower than
75% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. EXAS: -409.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3463.3  Med: -1718.22 Max: -409.5
Current: -409.5
-3463.3
-409.5
3-Year Revenue Growth Rate 151.60
EXAS's 3-Year Revenue Growth Rate is ranked higher than
99% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. EXAS: 151.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.2 Max: 302.1
Current: 151.6
0
302.1
3-Year EBITDA Growth Rate 31.60
EXAS's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. EXAS: 31.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.4  Med: -11.95 Max: 46.1
Current: 31.6
-39.4
46.1
3-Year EPS without NRI Growth Rate 33.20
EXAS's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. EXAS: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.1  Med: -14.35 Max: 46.5
Current: 33.2
-43.1
46.5
GuruFocus has detected 3 Warning Signs with Exact Sciences Corp $EXAS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAS's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

EXAS Guru Trades in Q2 2016

Joel Greenblatt 17,669 sh (New)
Columbia Wanger 770,000 sh (New)
PRIMECAP Management 4,516,300 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Steven Cohen 507,175 sh (-32.15%)
» More
Q3 2016

EXAS Guru Trades in Q3 2016

Jim Simons 365,300 sh (New)
Paul Tudor Jones 32,756 sh (New)
Joel Greenblatt 53,252 sh (+201.39%)
Steven Cohen Sold Out
PRIMECAP Management 4,491,300 sh (-0.55%)
Columbia Wanger 558,434 sh (-27.48%)
» More
Q4 2016

EXAS Guru Trades in Q4 2016

Steven Cohen 153,000 sh (New)
Columbia Wanger 864,133 sh (+54.74%)
PRIMECAP Management 4,491,300 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
» More
Q1 2017

EXAS Guru Trades in Q1 2017

Joel Greenblatt 56,048 sh (New)
Jim Simons 351,300 sh (New)
Pioneer Investments 62,559 sh (New)
Steven Cohen 2,500,476 sh (+1534.30%)
PRIMECAP Management 4,491,300 sh (unchged)
Columbia Wanger 353,799 sh (-59.06%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:NAS:PRXL, NYSE:ALR, OTCPK:SWTUY, NAS:BRKR, NYSE:CRL, NAS:VWR, OTCPK:CZMWY, NAS:PRAH, NAS:NEOG, NAS:ICLR, NAS:AXDX, NAS:MYGN, NAS:FMI, NAS:VREX, NAS:MEDP, NAS:ABAX, NAS:KANG, NAS:GHDX, NAS:DXCM, NAS:ALOG » details
Traded in other countries:EXK.Germany,
Headquarter Location:USA
Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non‑invasive, patient friendly screening test called Cologuard(R).

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - May 18, 2017

Exact Sciences Corp. (NASDAQ:EXAS) develops noninvasive molecular screening tests for the early detection and prevention of colorectal cancer. We originally invested in the company because Cologuard, its revolutionary product, exhibited low market penetration and significant opportunity for continued adoption. Test accuracy versus other non-invasive tests has led to improved adoption rates and recent annual revenue growth in excess of 150%. Large commercial insurer, Aetna, recently announced its decision to cover the screening for qualified members. In this positive environment, Exact Sciences raised its test volume expectations to 415,000 for the year and noted meaningful gross margin improvement as its business model continues to scale faster than expected. As such, we are maintaining our position.



From Meridian Growth Funds first-quarter 2017 shareholder commentary.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp Guru stock highlight
Exact Sciences Corp. (NASDAQ:EXAS) develops noninvasive molecular screening tests for the early detection and prevention of colorectal cancer. We originally invested in the company because Cologuard, its revolutionary product, exhibited low market penetration and significant opportunity for continued adoption. Test accuracy versus other non-invasive tests has led to improved adoption rates and recent annual revenue growth in excess of 150%. Large commercial insurer, Aetna, recently announced its decision to cover the screening for qualified members. In this positive environment, Exact Sciences raised its test volume expectations to 415,000 for the year and noted meaningful gross margin improvement as its business model continues to scale faster than expected. As such, we are maintaining our position. Read more...

Ratios

vs
industry
vs
history
PB Ratio 11.42
EXAS's PB Ratio is ranked lower than
80% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. EXAS: 11.42 )
Ranked among companies with meaningful PB Ratio only.
EXAS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 6.83 Max: 36.44
Current: 11.42
1.69
36.44
PS Ratio 25.58
EXAS's PS Ratio is ranked lower than
89% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. EXAS: 25.58 )
Ranked among companies with meaningful PS Ratio only.
EXAS' s PS Ratio Range Over the Past 10 Years
Min: 9.28  Med: 46.5 Max: 1325.45
Current: 25.58
9.28
1325.45
EV-to-EBIT -21.19
EXAS's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. EXAS: -21.19 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.7  Med: -11 Max: -0.3
Current: -21.19
-32.7
-0.3
EV-to-EBITDA -23.03
EXAS's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. EXAS: -23.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.4  Med: -11.6 Max: -0.4
Current: -23.03
-33.4
-0.4
Current Ratio 10.23
EXAS's Current Ratio is ranked higher than
93% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. EXAS: 10.23 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.75 Max: 50.84
Current: 10.23
1.02
50.84
Quick Ratio 9.97
EXAS's Quick Ratio is ranked higher than
93% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. EXAS: 9.97 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.75 Max: 50.84
Current: 9.97
1.02
50.84
Days Inventory 53.49
EXAS's Days Inventory is ranked higher than
57% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. EXAS: 53.49 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 53.49  Med: 79.66 Max: 169.5
Current: 53.49
53.49
169.5
Days Sales Outstanding 44.53
EXAS's Days Sales Outstanding is ranked higher than
87% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. EXAS: 44.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.32  Med: 45.66 Max: 279.33
Current: 44.53
31.32
279.33
Days Payable 6.12
EXAS's Days Payable is ranked lower than
93% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. EXAS: 6.12 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 5.73  Med: 1526.07 Max: 249295
Current: 6.12
5.73
249295

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.80
EXAS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. EXAS: -15.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -217.1  Med: -13.35 Max: -1
Current: -15.8
-217.1
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.14
EXAS's Price-to-Net-Cash is ranked higher than
57% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. EXAS: 15.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EXAS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.63 Max: 90
Current: 15.14
2.02
90
Price-to-Net-Current-Asset-Value 13.31
EXAS's Price-to-Net-Current-Asset-Value is ranked higher than
50% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. EXAS: 13.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.98  Med: 6.42 Max: 60
Current: 13.31
1.98
60
Price-to-Tangible-Book 11.44
EXAS's Price-to-Tangible-Book is ranked lower than
63% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. EXAS: 11.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.87  Med: 5.95 Max: 33.71
Current: 11.44
1.87
33.71
Price-to-Median-PS-Value 0.55
EXAS's Price-to-Median-PS-Value is ranked higher than
84% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. EXAS: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.36 Max: 185.2
Current: 0.55
0.24
185.2
Earnings Yield (Greenblatt) % -4.71
EXAS's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. EXAS: -4.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -106.22  Med: 0 Max: 41.6
Current: -4.71
-106.22
41.6

More Statistics

Revenue (TTM) (Mil) $132.9
EPS (TTM) $ -1.47
Beta1.13
Short Percentage of Float27.98%
52-Week Range $5.53 - 36.14
Shares Outstanding (Mil)111.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 196 296 469
EPS ($) -1.41 -0.92 -0.12
EPS without NRI ($) -1.41 -0.92 -0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Exact Sciences Corp May 18 2017 
Meridian Growth Fund 1Q 2017 Commentary May 18 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Exact Sciences Corp May 15 2017 
EXACT (EXAS) ALERT: J&W Investigates Exact Sciences; Encourages Investors to Contact the Firm May 15 2017 
Exact Sciences to participate in Bank of America Merrill Lynch Healthcare Conference May 01 2017 
Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 perc Apr 27 2017 
CMS includes Cologuard in updated Medicare Advantage Star Ratings Apr 04 2017 
Exact Sciences to host first-quarter 2017 results webcast and call Mar 31 2017 
Whitney Tilson's Robin Hood Conference Presentation Nov 19 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 

More From Other Websites
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees May 19 2017
ETFs with exposure to EXACT Sciences Corp. : May 19, 2017 May 19 2017
Is Exact Sciences on Borrowed Time? May 16 2017
Analyst Leaves Exact Sciences CEO Meeting With 'Fortified Confidence' Despite Recent Controversy May 16 2017
Why One Analyst Says Citron Got Exact Sciences Wrong May 16 2017
The Market In 5 Minutes May 16 2017
Today's Research Reports on Stocks to Watch: Ionis Pharmaceuticals and Exact Sciences Corporation May 16 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Exact Sciences Corporation... May 15 2017
Analyst refutes ‘flawed’ Citron Research report on Exact Sciences May 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Exact Sciences... May 15 2017
The short seller who uncovered Valeant has found his next target in health care May 15 2017
Exact Sciences: Nothing to See Here? May 15 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Exact Sciences Corporation May 15 2017
UPDATE: Exact Sciences Corp. stock drops 3% after short-seller Citron Research targets its colon... May 15 2017
EXACT (EXAS) ALERT: J&W Investigates Exact Sciences; Encourages Investors to Contact the Firm May 15 2017
Exact Sciences CEO and short-seller go mano-a-mano on CNBC, stock pares losses May 15 2017
Famed short-seller Andrew Left battles the CEO of his lat... May 15 2017
Short-seller's bear debate on Exact Sciences May 15 2017
Exact Sciences: Signs Say…Sticky? May 15 2017
3 Best Stocks in Personalized Medicine May 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat